Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer
Checked against the public recordLast updated Dec 5, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Biological: Nivolumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Non small cell lung cancer (Squamous or non-squamous) * At least one prior anti-cancer therapy that did not work * ECOG Performance Scale 0-1 Exclusion Criteria: * Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug * Active, known or suspected autoimmune disease or infection * Prior immuno-oncology therapy * Corticosteroids within 2 weeks of study drug administration Other protocol defined inclusion/exclusion criteria could apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Alabama OncologyBirmingham, Alabama
- Los Angeles Hematology Oncology Medical GroupLos Angeles, California
- St Vincent Frontier Cancer CenterBillings, Montana
- Broome OncologyJohnson City, New York
- Guthrie Medical Group SayreSayre, Pennsylvania
- Local Institution - 0015Kingston, Ontario
- Local Institution - 0014Oshawa, Ontario
- Local Institution - 0001Toronto, Ontario
- Local Institution - 0017Nagoya, Aichi-ken
- Local Institution - 0023Osaka, Osaka
- Local Institution - 0018Koto-ku, Tokyo
- Local Institution - 0016Tokyo
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 5, 2022. Always confirm current availability with the study team.